To the Editor: Su et al.
In Response: We agree and are aware of Dr. Coggin's statements on oncofetal antigen immunogenicity; however, his criticisms are based on major misconceptions regarding the vaccine approach used in our study (1) and do not relate to our stated objectives and conclusions. As clearly shown in the title and text of our publication (1), renal tumor RNA-transfected dendritic cells and not oncofetal antigen mRNA-transfected dendritic cells were used for vaccination and stimulated T-cell responses that, in part, contained reactivities against oncofetal antigen, telomerase (human telomerase reverse transcriptase), and G250. Oncofetal antigen mRNA-transfected dendritic cells were not used to immunize patients or to stimulate T-cell responses in vitro but were merely used as surrogate targets in IFN-␥ ELISPOT assays to determine antigen-specific T-cell frequencies contained in the vaccine-induced, tumor-specific T-cell response. In the same manner, telomerase (human telomerase reverse transcriptase)-and G250 mRNA-transfected dendritic cells were also used as surrogate targets without further expanding on the biology or immunology of these self-antigens. It was never our intent to provide quantitative comparisons on the immunogenicity of each antigen, but rather to provide evidence on the polyclonality of the vaccine-induced T-cell response suggested in prior studies performed by our group.
Thank you for the opportunity to respond to Dr. Coggin's letter.
